International Journal of Tumor Therapy
p-ISSN: 2163-2189 e-ISSN: 2163-2197
2014; 3(1): 1-9
doi:10.5923/j.ijtt.20140301.01
Visakh Prabhakar 1, Ranganathan Balasubramanian 2, Priyanka Sathe 3, C. Murali Krishna 3, Aarti Juvekar 4
1Department of Pharmacy, Birla Institute of Technology and Sciences, Pilani Campus, Rajasthan-333031, India
2Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Health Sciences Campus, Kochi, Kerala-682041, India
3Chilakapati Laboratory, Cancer Research Institute (CRI), Advanced centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai-410210, India
4Anti-Cancer Drug Screening Facility (ACDSF), Advanced centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai-410210, India
Correspondence to: C. Murali Krishna , Chilakapati Laboratory, Cancer Research Institute (CRI), Advanced centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai-410210, India.
Email: |
Copyright © 2012 Scientific & Academic Publishing. All Rights Reserved.
Cancer is a continuously adapting dynamic condition for which investigation of novel treatment strategies constitutes an integral component in its management. As part of the continuing efforts from the global community directed at eradication of cancer, we were interested in evaluating the cytotoxic potential of a series of chalcone derivatives. The study also contributes towards a preliminary understanding of the structure-activity relationship of synthetic chalcone derivatives. We screened various A-ring monosubstituted chalcone derivatives against five selected human cancer cell lines using the sulforhodamine B assay. Our in vitro observations indicated the previously established characteristic biphasic response of the chalcones. Moreover, it was found that the different substitutions at the A-ring were found to suppress the cytotoxic activity, which was evident from higher growth suppression by the unsubstituted chalcone compared to the substituted derivatives. The compound 4c exhibited similar activity to that of the unsubstituted derivative, indicating that the methyl group is not detrimental to activity. It was observed that the tested compounds were most effective on the A2780 ovarian cancer cell line exhibiting GI50 value ranging from 20-66 µM. Moreover, the analogs proved to be least cytotoxic in the HepG2 cell line with GI50 values that ranged from 39-100 µM. This study may act as a preliminary step towards understanding substituent effects on the cytotoxic activity profiles of chalcone derivatives emphasising on A-ring substituted moieties.
Keywords: Chalcones, Cytotoxicity, Cancer Cell Lines, Sulforhodamine B assay
Cite this paper: Visakh Prabhakar , Ranganathan Balasubramanian , Priyanka Sathe , C. Murali Krishna , Aarti Juvekar , In Vitro Anticancer Activity of Monosubstituted Chalcone Derivatives, International Journal of Tumor Therapy, Vol. 3 No. 1, 2014, pp. 1-9. doi: 10.5923/j.ijtt.20140301.01.
Figure 1. Basic chalcone skeleton with substituted rings A and B |
Scheme 1. Synthesis of target chalcone derivatives |
(1) |
(2) |
Figure 2. Effect of different chalcone derivatives on the percentage growth inhibition of the U373MG cell line[Values are Mean ± SEM of 3 replicates each. *P<0.05, VC = Vehicle Control (DMSO)] |
Figure 3. Effect of different chalcone derivatives on the percentage growth inhibition of the MCF-7 cell line[Values are Mean ± SEM of 3 replicates each. *P<0.05, VC = Vehicle Control (DMSO)] |
Figure 4. Effect of different chalcone derivatives on the percentage growth inhibition of the HepG2 cell line[Values are Mean ± SEM of 3 replicates each. *P<0.05, VC = Vehicle Control (DMSO)] |
Figure 5. Effect of different chalcone derivatives on the percentage growth inhibition of the K562 cell line[Values are Mean ± SEM of 3 replicates each. *P<0.05, VC = Vehicle Control (DMSO)] |
Figure 6. Effect of different chalcone derivatives on the percentage growth inhibition of the A2780 cell line[Values are Mean ± SEM of 3 replicates each. *P<0.05, VC = Vehicle Control (DMSO)] |
|
[1] | Rahman M. A., 2011, Chalcone: A valuable insight into the recent advances and potential pharmacological activities., Chem. Sci. J., 2011, CSJ-29. |
[2] | Awasthi, S. K., Mishra, N., Kumar, B., Sharma, M., Bhattacharya, A., Mishra, L. C., and Bhasin, V. K., 2009, Potent antimalarial activity of newly synthesized substituted chalcone analogues in vitro., Med. Chem. Res., 18(17), 407–420. |
[3] | Cheng, M. S., Shili, R., and Kenyon, G. A., 2000, Solid phase synthesis of chalcones by Claisen-Schmidt condensations., Chin. Chem. Lett., 11(10), 851–854. |
[4] | Lim, S. S., Kim, H. S., and Lee, D. U., 2007, In vitro antimalarial activity of flavonoids and chalcones., Bull. Korean Chem. Soc., 28(12), 2495–2497. |
[5] | Achanta, G., Modzelewska, A., Feng, L., Khan, S. R., and Huang, P., 2006, A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome., Mol. Pharmacol., 70(1), 426–433. |
[6] | Lunardi, F., Guzela, M., Rodrigues, A. T., Corre, R., Eger-Mangrich, I., Steindel, M., Grisard, E. C., Assreuy, J., Calixto, J. B., and Santos, A. R. S., 2003, Trypanocidal and leishmanicidal properties of substitution-containingchalcones., Antimicrob. Agents Chemother., 47(4), 1449–1451. |
[7] | Yadav, H. L., Gupta, P., Pawar, P. S., Singour, P. K., and Patil, U. K., 2011, Synthesis and biological evaluation of anti- inflammatory activity of 1,3-diphenyl propenone derivatives., Med. Chem. Res., 20(4), 461–465. |
[8] | Hamdi, N., Fischmeister, C., Puerta, M. C., and Valerga, P., 2011, A rapid access to new coumarinyl chalcone and substituted chromeno[4,3-c]pyrazol-4(1H)-ones and their antibacterial and DPPH radical scavenging activities., Med. Chem. Res., 20(4), 522–530. |
[9] | Awasthi, S. K., Mishra, N., Dixit, S. K., Singh, A., Yadav, M., Yadav, S. S., and Rathaur, S., 2009, Antifilarial activity of 1,3-diarylpropen-1-one: Effect on glutathione-S-transferase, a phase-II detoxification enzyme., Am. J. Trop. Med. Hyg., 80(5), 764–768. |
[10] | Bag, S., and Ramar, S., 2009, Synthesis and biological evaluation of α,β-unsaturated ketone as potential antifungal agents., Med. Chem. Res., 18(4), 309–316. |
[11] | Yayli, N., Ucuncu, O., Yasar, A., Kucuk, M., Akyuz, E., and Karaoglu, S. A., 2006, Synthesis and biological activities of N-alkyl derivatives of o-, m-, and p-nitro (E)-4-azachalcones and stereoselective photochemistry in solution with theoretical calculations., Turk. J. Chem., 30(4), 505–514. |
[12] | Kaushik, S., Kumar, N., and Drabu, S., 2010, Synthesis and anticonvulsant activities of phenoxychalcones., T. Ph. Res., 3, 257–262. |
[13] | Zarghi, A., Zebardast, T., Hakimion, F., Shirazi, F. H., Rao, P. N. P., and Knaus E. E., 2006, Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors., Bioorg. Med. Chem., 14(20), 7044–7050. |
[14] | Ducki, S., 2007, The development of chalcones as promising anticancer agents., IDrugs, 10(1), 42–46. |
[15] | Lawrence, N. J., and McGown, A. T., 2005, The chemistry and biology of antimitotic chalcones and related enone systems., Curr. Pharm. Des., 11(13), 1679–1693. |
[16] | Nowakowska, Z., 2007, A review of anti-infective and anti-inflammatory chalcones., Eur. J. Med. Chem., 42(2), 125–137. |
[17] | Ducki, S., 2009, Antimitotic chalcones and related compounds as inhibitors of tubulin assembly., Anticancer Agents Med. Chem., 9(3), 336–347. |
[18] | Peyrot, V., Leynadier, D., Sarrazin, M., Briand, C., Rodriquez, A., Nieto, J. M., and Andreu, J. M., 1989, Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048 - a powerful and reversible microtubule inhibitor., J. Biol. Chem., 264(35), 21296 – 21301. |
[19] | Ducki, S., Rennison, D., Woo, M., Kendall, A., Chabert, J. F. D., McGown, A. T., and Lawrence, N. J., 2009, Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity., Bioorg. Med. Chem., 17(22), 7698–7710. |
[20] | Boumendjel, A., Boccard, J., Carrupt, P. A., Nicolle, E., Blanc, M., Geze, A., Choisnard, L., Wouessidjewe, D., Matera, E. L., and Dumontet, C., 2008, Antimitotic and antiproliferative activities of chalcones: Forward structure -activity relationship., J. Med. Chem., 51(7), 2307–2310. |
[21] | Szliszka, E., Czuba, Z. P., Mazur, B., Sedek, L., Paradysz, A., and Krol, W., 2010, Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells., Int. J. Mol. Sci., 11(1), 1–13. |
[22] | Selassie, C. D., Shusterman, A. J., Kapur, S., Verma, R. P., Zhang, L., and Hansch, C., 1999, On the toxicity of phenols to fast growing cells. A QSAR model for a radical-based toxicity., J. Chem. Soc., Perkin Trans. 2, 1999(12), 2729–2733. |
[23] | Sabzevari, O., Galati, G., Moridani, M. Y., Siraki, A., and O'Brien, P. J., 2004, Molecular cytotoxic mechanisms of anticancer hydroxychalcones., Chem. Biol. Interact., 148 (1-2), 57–67. |
[24] | Ducki, S., Forrest, R., Hadfield, J. A., Kendall, A., Lawrence, N. J., McGown, A. T., and Rennison, D., 1998, Potentantimitotic and cell growth inhibitory properties of substituted chalcones., Bioorg. Med. Chem. Lett., 8(9), 1051–1056. |
[25] | Vichai, V., and Kirtikara, K., 2006, Sulforhodamine B colorimetric assay for cytotoxicity screening., Nat. Protoc., 1(3), 1112–1116. |
[26] | Hijova, E., 2006, Bioavailability of chalcones., Bratisl. Lek. Listy, 107(3), 80–84. |
[27] | Zhang, E. H., Wang, R. F., Guo, S. Z., and Liu, B., 2013, An update on antitumor activity of naturally occurring chalcones., J. Evid. Based Complement. Altern. Med., 2013, 1–22. |
[28] | Shibata, S., 1994, Anti-tumorigenic chalcones., Stem Cells, 12(1), 44–45. |
[29] | Araújo, J. R., Gonçalves, P., and Martel, F., 2011, Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines., Nutr. Res., 31(2), 77–87. |
[30] | [30] Padhye, S., Ahmad, A., Oswal, N., Dandawate, P., Rub, R. A., Deshpande, J., Swamy, K. V., and Sarkar, F. H., 2010, Fluorinated 2’-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities., Bioorg. Med. Chem. Lett., 20(19), 5818–5821. |
[31] | Snijman, P. W., Swanevelder, S., Joubert, E., Green, I. R., and Gelderblom, W. C. A., 2007, The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): Some dose-response effects on mutagen activation-flavonoid interactions., Mutat. Res., 631(2), 111–123. |
[32] | Van der Woude, H., Gliszczynska-Swiglo, A., Struijs, K., Smeets, A., Alink, G. M., and Rietjens, I. M. C. M., 2003, Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans., Cancer Lett., 200(1), 41–47. |
[33] | Van Erk, M. J., Roepman, P., Van der Lende, T. R., Stierum, R. H., Aarts, J. M., Van Bladeren, P. J., and Van Ommen, B., 2005, Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro., Eur. J. Nutr., 44(3), 143–156. |
[34] | Aruoma, O., 2003, Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods., Mutat. Res., 523, 9–20. |
[35] | Galati, G., and O’Brien, P. J., 2004, Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties., Free Radic. Biol. Med., 37(3), 287–303. |
[36] | Azmi, A. S., Bhat, S. H., Hanif, S., and Hadi, S. M., 2006, Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties., FEBS Lett., 580(2), 533–538. |
[37] | Lee, K. W., Hur, H. J., Lee, H. J., and Lee, C. Y., 2005, Antiproliferative effects of dietary phenolic substances and hydrogen peroxide., J. Agric. Food Chem., 53(6), 1990–1995. |
[38] | Syam, S., Abdelwahab, S. I., Al-Mamary, M. A., and Mohan, S., 2012, Synthesis of chalcones with anticancer activities., Molecules, 17(6), 6179–6195. |